摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

噻唑并[5,4-d]嘧啶-5,7(4H,6H)-二酮 | 5082-82-6

中文名称
噻唑并[5,4-d]嘧啶-5,7(4H,6H)-二酮
中文别名
噻唑并[5,4-D]嘧啶-5,7(4H,6H)-二酮;噻唑并[5,4-D]嘧啶-5,7-二醇
英文名称
4H-thiazolo[5,4-d]pyrimidine-5,7-dione
英文别名
4H-Thiazolo[5,4-d]pyrimidin-5,7-dion;4H-[1,3]thiazolo[5,4-d]pyrimidine-5,7-dione
噻唑并[5,4-d]嘧啶-5,7(4H,6H)-二酮化学式
CAS
5082-82-6
化学式
C5H3N3O2S
mdl
MFCD18533747
分子量
169.164
InChiKey
XYKSLGUQLMACHQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    >360 °C
  • 密度:
    1.626

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    99.3
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:42223486c9c0f7c7d5c6521f3a4394c1
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] IRAK INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'IRAK ET LEURS UTILISATION
    申请人:NIMBUS IRIS INC
    公开号:WO2015048281A1
    公开(公告)日:2015-04-02
    The present invention provides compounds, compositions thereof, and methods of using the same.
    本发明提供了化合物、其组合物以及使用它们的方法。
  • [EN] FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX<br/>[FR] PYRIMIDINES FUSIONNÉES EN TANT QU'INHIBITEURS DU COMPLEXE P97
    申请人:ZHOU HAN-JIE
    公开号:WO2014015291A1
    公开(公告)日:2014-01-23
    Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.
    本发明揭示了一种融合嘧啶化合物,其具有饱和、不饱和或芳香性A环与嘧啶环融合,并在嘧啶环的2位具有复杂的取代基,在4位具有取代胺基,以及在其他位置可选地具有取代的脂肪族、功能性和/或芳香性组分的嘧啶环和A环。这些化合物是包含p97的AAA蛋白酶复合物的抑制剂,是治疗与p97生物活性相关的疾病如癌症的有效药物。
  • Azole Series. I. Reaction of 2-(Acylamino)thioacetamides, leading to 5-Aminothiazoles and to Thiazolo[5, 4-d]pyrimidines.
    作者:Minoru Sekiya、Yoshiro Osaki
    DOI:10.1248/cpb.13.1319
    日期:——
    Formation of 5-acetamido-substituted thiazoles was found to be readily effective on heating 2-(acylamino)thioacetamides with acetic anhydride. In additon, preparation of some starting 2-(acylamino)thioacetamides is described and 5-acetamidothiazole-4-carboxamides obtained by the thiazole formation reaction were led to some thiazolo[5, 4-d]pyrimidines.
    研究发现,用乙酸酐加热 2-(酰氨基)硫代乙酰胺很容易生成 5-乙酰胺基取代的噻唑。此外,还介绍了一些 2-(酰氨基)硫代乙酰胺起始物的制备方法,并通过噻唑形成反应获得了 5-乙酰胺基噻唑-4-甲酰胺,从而得到了一些噻唑并[5, 4-d]嘧啶。
  • The synthesis of bicyclic nucleosides related to uridine, 4-(β-<scp>D</scp>-ribofuranosyl)thiazolo[5,4-d]pyrimidines
    作者:Charles L. Schmidt、William J. Rusho、Leroy B. Townsend
    DOI:10.1039/c29710001515
    日期:——
    The silyl alkylation procedure has furnished the first thiazolo [5,4-d]pyrimidine nucleoside (both α and β anomers isolated and characterized), and the site of alkylation has been established by a comparison of the u.v. spectra of the nucleoside and model N-methyl compounds.
    甲硅烷基化反应过程提供了第一个噻唑并[5,4- d ]嘧啶核苷(分离并表征了α和β端基异构体),并且通过比较核苷和N型紫外光谱确定了烷基化位点-甲基化合物。
  • COMPOUND HAVING KHK INHIBITORY EFFECT
    申请人:Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.
    公开号:EP4083034A1
    公开(公告)日:2022-11-02
    A compound having a KHK inhibitory effect, or pharmaceutically acceptable salts thereof, and use thereof in the preparation of a medicament for treating a disease associated with KHK kinase abnormal expression. Provided is a compound as represented by formula (III) or a pharmaceutically acceptable salt thereof.
    具有KHK抑制作用的化合物,或其药学上可接受的盐,及其在制备用于治疗与KHK激酶异常表达相关的疾病的药物中的用途。本发明提供了一种如式(III)所示的化合物,或其药学上可接受的盐。
查看更多

同类化合物

噻唑并[5,4-d]嘧啶-7(4H)-酮 噻唑并[5,4-d]嘧啶-5,7(4H,6H)-二酮 噻唑并[5,4-d]嘧啶-2(1H)-酮 噻唑并[5,4-d]嘧啶,5-氯- 噻唑[5,4-D]嘧啶-2-胺 叔丁基-(7-氯噻唑并[5,4-d]嘧啶-2-基)-胺 [1,3]噻唑并[5,4-D]嘧啶-7-胺 N7-丁基-n2-苯基噻唑并[5,4-d]嘧啶-2,7-二胺 N7-(4-甲氧基苯基)-n2-苯基噻唑并[5,4-d]嘧啶-2,7-二胺 N7-(3-氯苯基)-n2-苯基噻唑并[5,4-d]嘧啶-2,7-二胺 N2-苯基-n7-(3,4,5-三甲氧基苄基)噻唑并[5,4-d]嘧啶-2,7-二胺 N2,N7-二苯基-噻唑并[5,4-d]嘧啶-2,7-二胺 N-(7-氯-2-甲基噻唑并[5,4-D]嘧啶-5-基)新戊酰胺 7-氯噻唑并[5,4-D]嘧啶 7-氯-N-(邻甲苯基)噻唑并[5,4-D]嘧啶-2-胺 7-氯-5-甲基-[1,3]噻唑并[5,4-d]嘧啶 7-氯-5-(三氟甲基)[1,3]噻唑并[5,4-d]嘧啶 7-氨基-噻唑并[5,4-d]嘧啶-2(1H)-硫酮 7-(甲硫基)噻唑并[5,4-D]嘧啶-2-羧酸甲酯 5-甲硫基-9-硫杂-2,4,7-三氮杂双环[4.3.0]壬-2,4,7,10-四烯 5,7-二氯噻唑并[5,4-D]嘧啶 5,7-二氯-2-甲基-噻唑并[5,4-d]嘧啶 4-(5-氯噻唑并[5,4-D]嘧啶-7-基)吗啉 2-苯胺基[1,3]噻唑并[5,4-d]嘧啶-7-醇 2-苯基噻唑并[5,4-d]嘧啶-7-胺 2-甲基-4H-噻唑并[5,4-d]嘧啶-5,7-二酮 2-(甲基硫代)-噻唑并[5,4-d]嘧啶-7(4H)-酮 2,7-二氯噻唑并[5,4-D]嘧啶 2,5-二氯噻唑并[5,4-d]嘧啶 2,5-二氨基-6H-[1,3]噻唑并[4,5-e]嘧啶-7-酮 1-(7-氯噻唑并[5,4-d]嘧啶-2-基)-1,3-二甲基硫脲 1,3-二苄基-1-(7-氯噻唑并[5,4-d]嘧啶-2-基)硫脲 (7-氯噻唑并[5,4-d]嘧啶-2-基)苯胺 (7-氯噻唑并[5,4-d]嘧啶-2-基)异丙胺 (7-氯噻唑并[5,4-d]嘧啶-2-基)-对甲苯-胺 (7-氯噻唑并[5,4-d]嘧啶-2-基)-吡啶-3-基-胺 (7-氯噻唑并[5,4-d]嘧啶-2-基)-(4-甲氧基苯基)胺 (7-氯噻唑并[5,4-d]嘧啶-2-基)-(2,6-二甲基苯基)胺 (6CI,7CI,8CI,9CI)-噻唑并[5,4-d]嘧啶 ethyl 5-chlorothiazolo[5,4-d]pyrimidin-2-ylcarbamate N5-(3-fluorobenzyl)-2-(2-furanyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 2-methyl-N5-(thiophen-2ylmethyl)thiazolo[5,4-d]pyrimidine-5,7-diamine 2-(pyrazin-2-yl)-N5-(thiophen-2-ylmethyl)thiazolo[5,4-d]pyrimidine-5,7-diamine 2-(thiophen-2-yl)-N5-(thiophen-2-yl-methyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 2-phenyl-N5-(thiophen-2-ylmethyl)thiazolo[5,4-d]pyrimidine-5,7-diamine 2-(5-methylfuran-2-yl)-N5-(thiophen-2-yl-methyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 2-(furan-2-yl)-N5-(thiophen-2-yl-methyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine (R)-N-benzyl-2-(5-ethyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxamide 2-(4-chlorophenylamino)-7-chlorothiazolo[5,4-d]pyrimidine 5-chlorothiazolo[5,4-d]pyrimidin-2-amine